Afexa Life Sciences Inc.

Afexa Life Sciences Inc.

March 22, 2006 05:30 ET

CV Technologies-Maker of COLD-fX'R'-Begins Trading on the TSX

EDMONTON, ALBERTA--(CCNMatthews - March 22, 2006) -

Editors Note: A photo of CV Technologies' CEO and spokesperson Don Cherry launching the trading day will be available on the CP picture wire via PR Direct.

CV Technologies Inc. (TSX:CVQ) today began trading its common shares on the Toronto Stock Exchange, trading under the symbol (CVQ), previously used on the TSX - Venture Exchange.

CV Technologies Inc. was selected the TSX Venture Exchange's top performing company in 2005. CV Technologies president and CEO Dr. Jacqueline Shan says, "This move fulfills a major corporate objective that management had set for this year. We believe our investors will see this as a natural and timely progression in our development. It is part of our business plan and coincides with our announcement at our Annual General Meeting three weeks ago of our strategy to enter the U.S."

Dr. Shan added, "A listing on the TSX could bring our company more visibility, attract analysts and institutional investors and offer more stability to the Company in the capital markets."

As part of the listing ceremony, Dr. Shan, along with COLD-fX spokesperson Don Cherry and other company executives launched the trading day on the TSX.


CV Technologies, founded in 1992, is a global leader in the development and commercialization of naturally derived, evidence based, clinically tested medicines for disease prevention and health maintenance. The Company's lead product - COLD-fX®, - the top selling cold and flu remedy in Canada according to ACNielsen, strengthens the immune system and is widely used as a leading over the counter remedy for preventing and relieving cold and flu infection. COLD-fX® with its unique and patented mechanism of action was developed and standardized according to the Company's ChemBioPrint (CBP) process. The CBP process precisely identifies the chemical profile and biological activity of multi-active compounds in evidence-based natural therapeutics. The CBP process also provides a manufacturing protocol that ensures each batch of the final product delivers verifiable and provable health benefits.

Contact Information